A Phase 2 Trial of Zanidatamab with Chemotherapy for HER2-Positive Breast Cancer
Phase 2
125
about 4.9 years
18+
21 sites in CA, CO, FL +11
About this study
This trial is testing zanidatamab, a new drug, when combined with chemotherapy in people with HER2-positive early-stage breast cancer. The goal is to see if this combination is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin
- 2.Take Docetaxel
- 3.Take Paclitaxel
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, docetaxel, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pertuzumab, trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells), zanidatamab
infusion, injection, intravenous
Secondary: Event Free Survival (EFS), Number of Participants Discontinuing Study Treatment Due to TEAEs, Number of Participants with Treatment-emergent Adverse Events (TEAEs), Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library, Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE), Overall Survival (OS)
Oncology